Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer.

ABSTRACT:

Purpose

Prostate-specific membrane antigen (PSMA) targeting therapies such as Lutetium-177 (177Lu)-PSMA-617 are affecting outcomes from metastatic castration-resistant prostate cancer (mCRPC). However, a significant subset of patients have prostate cancer cells lacking PSMA expression, raising concerns about treatment resistance attributable at least in part to heterogeneous PSMA expression. We have previously demonstrated an association between high PSMA expression and DNA damage repair defects in mCRPC biopsies and therefore hypothesized that DNA damage upregulates PSMA expression.

Experimental design

To test this relationship between PSMA and DNA damage we conducted a screen of 147 anticancer agents (NCI/NIH FDA-approved anticancer "Oncology Set") and treated tumor cells

SUBMITTER: Sheehan B 

PROVIDER: S-EPMC9365343 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature